Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 1/20 | 0.44 |
| ▸ | GRM5 | P41594 | 2/20 | 0.42 |
| ▸ | HTR2A | P28223 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | FABP3 | P05413 | 2/20 | 0.40 |
| ▸ | FABP4 | P15090 | 2/20 | 0.40 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.40 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.38 |
| ▸ | HSP90AB1 | P08238 | 2/20 | 0.38 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.37 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.34 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5929499 | 0.82 | APP (0.50) | APPGRM5HTR2AMAPTFFAR1 | |
| SCHEMBL19455956 | 0.76 | APP (0.57) | APPGRM5HTR2AMAPTFFAR1 | |
| SCHEMBL28282150 | 0.71 | NPC1 (0.50) | APPGRM5HTR2AMAPTFFAR1 | |
| SCHEMBL2450399 | 0.70 | APP (0.80) | APPGRM5MAPTFFAR1KCNH2 | |
| SCHEMBL3796509 | 0.70 | APP (0.80) | APPGRM5MAPTFFAR1KCNH2 | |
| SCHEMBL30083107 | 0.69 | TDP1 (0.36) | FABP3FABP4GABRA1GABRB2FABP5 | |
| SCHEMBL18488464 | 0.69 | APP (0.43) | APPGRM5HTR2AMAPTFFAR1 | |
| SCHEMBL12378776 | 0.68 | FFAR1 (0.53) | APPGRM5HTR2AMAPTFFAR1 | |
| SCHEMBL2727228 | 0.68 | ROCK2 (0.49) | MAPTFABP3FABP4HSP90AA1GABRA1 | |
| SCHEMBL3808490 | 0.68 | TYR (0.49) | APPGRM5HTR2AMAPTFFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9101920-B2 | Palladium catalyst, method for its preparation and its use | H4SEP KFT (HU) | 2015-08-11 | — | — | US | disclosed |
| CN-103402949-B | A new palladium catalyst, method for its preparation and its use | H4SEP KFT | 2015-07-01 | — | — | CN | disclosed |
| US-9056314-B2 | Palladium catalyst, method for its preparation and its use | H4SEP KFT (HU) | 2015-06-16 | — | — | US | disclosed |
| US-20140012004-A1 | NEW PALLADIUM CATALYST, METHOD FOR ITS PREPARATION AND ITS USE | H4SEP KFT (HU) | 2014-01-09 | — | — | US | disclosed |
| CN-103402949-A | A new palladium catalyst, method for its preparation and its use | H4SEP KFT | 2013-11-20 | — | — | CN | disclosed |
| US-20130281700-A1 | PALLADIUM CATALYST, METHOD FOR ITS PREPARATION AND ITS USE | CHINOIN GYOGYSZER-ES VEGYESZETI TER-MEKEK GYARA ZRT (HU) | 2013-10-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130281700-A1 | PALLADIUM CATALYST, METHOD FOR ITS PREPARATION AND ITS USE | PDS5A, DDT, PDS5B | APP 3207/4885GRM5 580/4885HTR2A 4438/4885 |
| US-20140012004-A1 | NEW PALLADIUM CATALYST, METHOD FOR ITS PREPARATION AND ITS USE | DDT, PDS5A, PDS5B | APP 3446/4885GRM5 763/4885HTR2A 4424/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.